HSD3B1 Genotype and Outcomes With ADT After Radiotherapy for Localized Prostate Cancer - The ASCO Post

<em>HSD3B1</em> Genotype and Outcomes With ADT After Radiotherapy for Localized Prostate Cancer - The ASCO Post

HSD3B1 Genotype and Outcomes With ADT After Radiotherapy for Localized Prostate Cancer

By Matthew Stenger
Posted: 11/1/2017 10:21:55 AM
Last Updated: 11/1/2017 10:21:55 AM
Tweet this page

Key Points

• In patients receiving androgen-deprivation therapy for localized prostate cancer, the presence of the HSD3B1 (1245C) allele was associated with more rapid progression to metastasis after radiotherapy.
• No effect of the allele was found for the time to disease progression or overall survival.